GSK invests £10 million over five years to establish the Experimental Medicine Collaboration with the University of Oxford.
The GSK and University of Oxford Experimental Medicine Collaboration (EMC) is a pioneering partnership that aims to redefine the approach to studying and treating immune mediated inflammatory diseases. Through the integration of cutting-edge molecular insights with clinical advancements, the EMC will allow testing of multiple medicines across cellular mechanisms in parallel.
The EMC will be led by Oxford’s Professor Christopher Buckley, Kennedy Trust Feldmann Maini Professor of Translational Medicine and Director of the Oxford Experimental Medicine Clinical Research Facility (EMCRF), alongside Dr Eric Olson, Vice President and Head of Early Development Leaders at GSK.
The Oxford EMCRF, which involves close collaboration between the University of Oxford and Oxford University Hospitals NHS Foundation Trust, plays a key role in the clinical translational strategy of the NIHR Oxford Biomedical Research Centre and its 15 specialist research themes and is key enabling infrastructure for this collaboration.
GSK will provide a £10 million infrastructure grant for the Oxford EMCRF, a National Institute of Health and Care Research (NIHR) supported clinical research facility providing a resource for early phase, experimental medicine studies across the Oxford Medical Sciences Division.